Notably, CSCs seem not to addict to the oncogenic target or pathway for transformation (e.g., BCR/ABL for CML blasts but not CSCs) (165) but depend upon their unique survival pathways (166, 167). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.